StockNews.AI
JAGX
StockNews.AI
182 days

Jaguar Health Extends Collaboration for Possible Tropical Disease Priority Review Voucher and Cholera Indication for NP-300

1. Jaguar Health extends collaboration for NP-300 to address cholera-related diarrhea. 2. FDA's TDPRV program may enhance NP-300's development value amid limited PRVs.

3m saved
Insight
Article

FAQ

Why Bullish?

The extension of collaboration may increase investor confidence in JAGX's prospects, similar to past PRV sales boosting stock values.

How important is it?

News of drug development and PRV potential directly impacts JAGX's market positioning and financial outlook.

Why Long Term?

The focus on TDPRVs suggests ongoing value creation and sustained interest over time, resembling previous drug development successes.

Related Companies

NAPXVRTX
Priority Review Vouchers (PRVs) are transferable and, in past transactions by other companies, have sold for prices up to $350 million 1.3 to 4 million cholera cases and 21,000 to 143,000 cholera-related deaths occur each year worldwide SAN FRANCISCO, CA / ACCESS Newswire / February 18, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") and Jaguar family company Napo Pharmaceuticals ("Napo") today announced that, on January 29, 2025, they extended their collaboration with Streeterville related to Napo's plans to develop its NP-300 drug product candidate for the symptomatic relief of diarrhea and dehydration in cholera patients and pursue a possible Tropical Disease Priority Review Voucher ("TDPRV") from the U.S. Food and Drug Administration ("FDA") for this indication. With the sunset of the FDA's Rare Pediatric Disease PRV program in December 2024, and the sunset of the FDA's Medical Countermeasures PRV Program in October 2023, the TDPRV Program is currently the FDA's only active PRV program - so there will possibly be fewer PRVs available for purchase, which could increase the value of TDPRVs, spurring increased interest and investment in tropical diseases.

Related News